Form 4: Ocuphire Pharma Director Jay Pepose Receives Stock and Option Grants

Director Jay Pepose of Ocuphire Pharma, Inc. reports acquisition of restricted stock units and stock options.

Summary

• On April 11, 2024, Jay Pepose, a director of Ocuphire Pharma, Inc., reported the acquisition of 32,000 shares of common stock through restricted stock units and options to purchase 48,000 shares.
• The restricted stock units vest on April 11, 2025, contingent upon continued service.
• The stock options, with an exercise price of $1.79, vest in 12 equal monthly installments starting May 11, 2024, also subject to continued service.
• Following these transactions, Pepose directly owns 139,315 shares of Ocuphire Pharma's common stock and options to purchase 48,000 shares.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of restricted stock units and options to a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock grants and options are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Alnylam Pharmaceuticals and Vertex Pharmaceuticals also utilize stock options and restricted stock units to incentivize their executives and directors.
• The vesting schedules are typical, with monthly or annual vesting tied to continued service.

Stakeholder Impact

• The stock and option grants could potentially impact shareholders by diluting equity if the options are exercised.
• The grants incentivize the director to work towards the company's success, which benefits all stakeholders.

Key Dates